Stocktoria
HALOZYME THERAPEUTICS, INC. HALO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2003-01-30
HALOZYME THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.0B | $829.3M | $660.1M | $443.3M |
| R&D expense | — | $79.0M | $76.4M | $66.6M | $35.7M |
| SG&A expense | $207.1M | $154.3M | $149.2M | $143.5M | $50.3M |
| Operating income | $469.0M | $551.5M | $337.6M | $267.5M | $275.9M |
| Interest expense | — | — | $18.8M | $16.9M | $7.5M |
| Income tax | $150.0M | $113.0M | $66.7M | $46.8M | -$154.2M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M |
| EPS (diluted) | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 |
| Operating cash flow | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M |
| Free cash flow | $644.6M | $468.4M | $373.3M | $235.3M | $298.0M |
| Cash & equivalents | $133.8M | $115.8M | $118.4M | $234.2M | $118.7M |
| Inventory | $176.5M | $141.9M | $127.6M | $100.1M | $53.9M |
| Total assets | $2.5B | $2.1B | $1.7B | $1.8B | $1.1B |
| Total liabilities | $2.5B | $1.7B | $1.6B | $1.7B | — |
| Shareholders' equity | $48.8M | $363.8M | $83.8M | $169.8M | $197.0M |
Source: SEC EDGAR filings · CIK 0001159036 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.